Arch Oncology Appoints Drew Dennison to Board of Directors

BRISBANE, CA and ST. LOUIS, MO, August 12, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Drew Dennison to the Company’s Board of Directors.

“Drew brings significant financial and operational experience to our Board of Directors as we work to advance our pipeline of novel antibody therapeutics,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “This is an important year for Arch Oncology, with additional preclinical data on AO-176 pointing to new clinical development opportunities and with our pipeline programs advancing. As we prepare for the future, we look forward to Drew’s contributions and welcome him to the Board of Directors.”

Drew Dennison, Managing Director at Lightchain Capital, LLC and Director for Arch Oncology, added, “Earlier this year, Lightchain led Arch Oncology’s Series B financing, based on our excitement about the leadership team that Julie assembled and the promise of the AO-176 clinical program. As AO-176 and the pipeline programs advance, I have become increasingly enthusiastic about the future of Arch Oncology. I look forward to working with the Board and senior leadership team at Arch Oncology, as the Company advances what we believe is a best-in-class antibody therapeutic in the anti-CD47 space.”

Drew Dennison is Managing Director at Lightchain Capital, LLC, the family office for Scottrade Founder and former Chief Executive Officer Rodger Riney. At Lightchain, Mr. Dennison is responsible for venture capital investments in the life science and technology sectors. He also assists the Riney Foundations with their philanthropic endeavors. Previously, Mr. Dennison served as the Chief Operating Officer and Chief Financial Officer at Scottrade Financial Services, Inc. He led the Company’s operations, technology, operations, finance, and strategic planning functions and worked at the Company for over a decade. Mr. Dennison led the sale of Scottrade to TD Ameritrade, then co-led the integration project, successfully combining the two companies. In addition, Mr. Dennison serves as Chairman of the Board of CareVet Holdings and as a Board Member of FinTech Studios.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain. For more information please visit

Media Contact:
Amy Figueroa
For Arch Oncology